|
|
 |
PROSTVAC®-VF
Therion is developing PROSTVAC®-VF as a new treatment option for men with prostate cancer. Therion's lead prostate cancer vaccine, PROSTVAC-VF, targets prostate-specific antigen (PSA), an antigen, or protein, associated with prostate tumor cells. In addition to PSA, PROSTVAC-VF also incorporates TRICOM�, Therion's proprietary costimulatory system designed to enhance and sustain the immune response against tumor cells. PROSTVAC-VF has been evaluated in a Phase I clinical study and a Phase II study is currently ongoing. Please visit the Clinical Studies section for more detailed information about PROSTVAC-VF.
According to the American Cancer Society, prostate cancer is one of the most common cancers affecting men in the United States, with an annual incidence of over 225,000 cases. It is estimated that the disease results in over 29,000 U.S. deaths annually. Current treatment options include surgery and radiation for localized tumors and hormone ablation therapy and chemotherapy in cases where the cancer has metastasized, or spread to other areas of the body. These treatment options carry many potential side effects, including impotence, incontinence, and loss of libido.
|
